Psoriasis
Conditions
Keywords
Amniotic membrane, Psoriasis, Treatment
Brief summary
Using of human amniotic membrane extra-cellular matrix as a topical treatment for improving Psoriasis Area and Severity Index (PASI).
Detailed description
Human amniotic membrane extra-cellular matrix was purchased from National center for radiation research and technology, Egypt, under commercial name REGE pro gel.
Interventions
COMBINATION_PRODUCTREGE pro
REGE pro is a patch of human amniotic membrane sterilized by gamma radiation
Sponsors
Egyptian Atomic Energy Authority
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* patients have psoriasis lesion
Exclusion criteria
* must stop other line of treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Scaling size decrement | 2 weeks | REGE pro gel decreased scaling size in patients with sever scales to moderate scale within two weeks, scaling size decrement from moderate to mild within two weeks, and from mild to complete curing within two weeks |
| Histopathological improvement | 6 weeks | Two biopsies were taken from each patient before and at the end of the treatment. It was noted that all histological signs as munro's microabscess and the elongation of rete ridges were absent. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Erythema disappearing | 4-6 weeks | REGE pro gel gradually decreased erythema in patients within 4-6 weeks, these data were collected from applied patients by questionnaire. |
Countries
Egypt
Outcome results
None listed